首页> 外文OA文献 >Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors

【2h】

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors

机译：通过将CSF1R抑制剂（PEXIDARTINIB / PLX3397）用抗PD-1抗体（PEMBROLIZUAB）组合治疗先进的黑色素瘤和其他实体肿瘤来研究双免疫抑制阻断的相1 / 2A研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J.C. Sachdev; S. Hu-Lieskovan; A. Patnaik; P.D. Eisenberg; A. Weise; M.A. Hutchinson; B. West; C. Gause; S. Tong; A. Ribas;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors [J] . Robert Wesolowski, Neelesh Sharma, Laura Reebel, Therapeutic advances in medical oncology. . 2019,第12期

机译：Pexidartinib（PLX3397），CSF-1R抑制剂和紫杉醇的相结合的相位记研究患者晚期实体瘤的患者
2. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor [J] . Rosenbaum Evan, Kelly Ciara, DAngelo Sandra P., The oncologist . 2019,第10期

机译：我在晚期胃肠道肿瘤患者中将Binimetinib（MEK162）与Pexidartinib（PLX3397）联合的阶段研究
3. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor [J] . Evan Rosenbaum, Chloe R. Mcfadyen, Christina R. Antonescu, The oncologist . 2019,第10期

机译：我在晚期胃肠道肿瘤患者中将Binimetinib（MEK162）与Pexidartinib（PLX3397）联合的阶段研究
4. Phase Ib study of the combination of pexidartinib (PLX3397) a CSF-1R inhibitor and paclitaxel in patients with advanced solid tumors [O] . Robert Wesolowski, Neelesh Sharma, Laura Reebel, 2019

机译：培西达替尼（PLX3397）CSF-1R抑制剂和紫杉醇联合治疗晚期实体瘤的Ib期研究
5. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor [O] . Evan Rosenbaum, Ciara Kelly, Sandra P. DAngelo, 2019

机译：我在先进的胃肠道基质肿瘤患者中将Binimetinib（MEK162）与Pexidartinib（PLX3397）相结合的阶段研究

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors

著录项

引文网络

相似文献

相关主题

期刊订阅